On the public citation graph
68 Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
0 signed · 852 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/cmmi.232openalex-snapshot
68 Ga‐PET: a powerful generator‐based alternative to cyclotron‐based PET radiopharmaceuticals
inferredcites →https://doi.org/10.1002/cne.903150208openalex-snapshot
Immunocytochemical localization of the N‐acetyl‐aspartyl‐glutamate (NAAG) hydrolyzing enzyme N‐acetylated α‐linked acidic dipeptidase (NAALADase)
inferredcites →https://doi.org/10.1002/ijc.21014openalex-snapshot
Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination
inferredcites →https://doi.org/10.1002/jcb.10661openalex-snapshot
Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer
inferredcites →https://doi.org/10.1007/s00259-008-0816-zopenalex-snapshot
Tetrafluorophenolate of HBED-CC: a versatile conjugation agent for 68Ga-labeled small recombinant antibodies
inferredcites →https://doi.org/10.1007/s00259-010-1392-6openalex-snapshot
68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours
inferredcites →https://doi.org/10.1007/s003350010240openalex-snapshot
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase
inferredcites →https://doi.org/10.1016/0020-708x(81)90174-5openalex-snapshot
A new 68Ge/68Ga radioisotope generator system for production of 68Ga in dilute HCl
inferredcites →https://doi.org/10.1016/s0969-8051(01)00246-3openalex-snapshot
Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC1/anti-Ga chelate antibodies and immunoscintigraphy with PET
inferredcites →https://doi.org/10.1021/bi801883vopenalex-snapshot
Pseudoirreversible Inhibition of Prostate-Specific Membrane Antigen by Phosphoramidate Peptidomimetics
inferredcites →https://doi.org/10.1021/jm100623eopenalex-snapshot
68 Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer
inferredcites →https://doi.org/10.1021/jm800765eopenalex-snapshot
Interactions between Human Glutamate Carboxypeptidase II and Urea-Based Inhibitors: Structural Characterization
inferredcites →https://doi.org/10.1021/jm801055hopenalex-snapshot
Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer
inferredcites →https://doi.org/10.1021/mp9000712openalex-snapshot
Design, Synthesis, and Preclinical Evaluation of Prostate-Specific Membrane Antigen Targeted 99mTc-Radioimaging Agents
inferredcites →https://doi.org/10.1056/nejmoa0810696openalex-snapshot
Mortality Results from a Randomized Prostate-Cancer Screening Trial
inferredcites →https://doi.org/10.1073/pnas.1735443100openalex-snapshot
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
inferredcites →https://doi.org/10.1091/mbc.e02-11-0731openalex-snapshot
A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen
inferredcites →https://doi.org/10.1158/0008-5472.can-04-1722openalex-snapshot
A Prostate-Specific Membrane Antigen-Targeted Monoclonal Antibody–Chemotherapeutic Conjugate Designed for the Treatment of Prostate Cancer
inferredcites →https://doi.org/10.1158/0008-5472.can-09-1682openalex-snapshot
Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2690openalex-snapshot
Radiolabeled Small-Molecule Ligands for Prostate-Specific Membrane Antigen:In vivoImaging in Experimental Models of Prostate Cancer
inferredcites →https://doi.org/10.1200/jco.2004.09.154openalex-snapshot
Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer
inferredcites →https://doi.org/10.2967/jnumed.106.036707openalex-snapshot
Influence of Chelate Conjugation on a Newly Identified Tumor-Targeting Peptide
inferredcites →https://doi.org/10.2967/jnumed.108.058487openalex-snapshot
PET Imaging of Prostate Cancer Xenografts with a Highly Specific Antibody against the Prostate-Specific Membrane Antigen
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4996194openalex-extracted
Synthesis and Study of Hynic Conjugated Psma Targeting Ligands for Prostate Cancer Diagnosis
inferred← citeshttps://doi.org/10.1002/2211-5463.12276openalex-snapshot
Mouse glutamate carboxypeptidase II ( GCPII ) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII
inferred← citeshttps://doi.org/10.1002/9781118697191.ch3openalex-snapshot
Coordination Chemistry and Ligand Design in the Development of Metal Based Radiopharmaceuticals
inferred← citeshttps://doi.org/10.1002/9781119300229.ch12openalex-snapshot
Chemical Probes Targeting Proteases for Imaging and Diagnostics in Cancer
inferred← citeshttps://doi.org/10.1002/9781119603627.ch32openalex-snapshot
Radionuclide Therapies and Correlative Imaging
inferred← citeshttps://doi.org/10.1002/ajoc.201900329openalex-snapshot
Prostate‐Specific Membrane Antigen (PSMA)‐Targeted Radionuclide Probes for Imaging and Therapy of Prostate Cancer
inferred← citeshttps://doi.org/10.1002/ange.201908964openalex-snapshot
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper‐64 with High Tumor Uptake and Retention
inferred← citeshttps://doi.org/10.1002/ange.202204072openalex-snapshot
Supramolecular Rotaxane‐Based Multi‐Modal Probes for Cancer Biomarker Imaging**
inferred← citeshttps://doi.org/10.1002/anie.201908964openalex-snapshot
A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper‐64 with High Tumor Uptake and Retention
inferred← citeshttps://doi.org/10.1002/anie.202204072openalex-snapshot
Supramolecular Rotaxane‐Based Multi‐Modal Probes for Cancer Biomarker Imaging**
inferred← citeshttps://doi.org/10.1002/ardp.202400890openalex-snapshot
FDA‐approved drugs featuring macrocycles or medium‐sized rings
inferred← citeshttps://doi.org/10.1002/chem.201803261openalex-snapshot
Chemical Kinetics of Radiolabelling Reactions
inferred← citeshttps://doi.org/10.1002/chem.201905202openalex-snapshot
Establishing Radiolanthanum Chemistry for Targeted Nuclear Medicine Applications
inferred← citeshttps://doi.org/10.1002/chem.71229openalex-snapshot
Small‐Molecule Targeted and Activatable Photoacoustic Probes for In Vivo Imaging: Design Principles and Recent Advances
inferred← citeshttps://doi.org/10.1002/chir.23376openalex-snapshot
New pharmaceuticals approved by FDA in 2020: Small‐molecule drugs derived from amino acids and related compounds
inferred← citeshttps://doi.org/10.1002/cmdc.201400055openalex-snapshot
Phosphinic Acid Functionalized Polyazacycloalkane Chelators for Radiodiagnostics and Radiotherapeutics: Unique Characteristics and Applications
inferred← citeshttps://doi.org/10.1002/cmdc.201900559openalex-snapshot
Synthesis, Labeling and Preclinical Evaluation of a Squaric Acid Containing PSMA Inhibitor Labeled with 68Ga: A Comparison with PSMA‐11 and PSMA‐617
inferred← citeshttps://doi.org/10.1002/cmdc.202100135openalex-snapshot
Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer
inferred← citeshttps://doi.org/10.1002/cmdc.202100210openalex-snapshot
A Structure‐Activity Relationship Study of Bimodal BODIPY‐Labeled PSMA‐Targeting Bioconjugates
inferred← citeshttps://doi.org/10.1002/cmdc.70320openalex-snapshot
Phosphinate or Urea? Synthesis and Biological Evaluation of Prostate Specific Membrane Antigen‐Targeted Fluorophores With Different Zinc‐Binding Motif
inferred← citeshttps://doi.org/10.1002/cmmi.1558openalex-snapshot
Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer
inferred← citeshttps://doi.org/10.1002/cncr.32039openalex-snapshot
Metastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or…
inferred← citeshttps://doi.org/10.1002/cnr2.1169openalex-snapshot
Comparison of prostate‐specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer
inferred← citeshttps://doi.org/10.1002/jlcr.3414openalex-snapshot
Prospects of medium specific activity 177 Lu in targeted therapy of prostate cancer using 177 Lu‐labeled PSMA inhibitor
inferred← citeshttps://doi.org/10.1002/jlcr.3563openalex-snapshot
Synthesis and evaluation of 68 Ga‐HBED‐CC‐EDBE ‐folate for positron‐emission tomography imaging of overexpressed folate receptors on CT26 tumor cells
inferred← citeshttps://doi.org/10.1002/jlcr.3582openalex-snapshot
Re‐thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals
inferred← citeshttps://doi.org/10.1002/jlcr.3712openalex-snapshot
Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
inferred← citeshttps://doi.org/10.1002/jlcr.3735openalex-snapshot
Designing tracers for PET imaging of the urokinase‐type plasminogen activator receptor from a cyclic uPA‐derived peptide: first in vitro evaluations
inferred← citeshttps://doi.org/10.1002/jlcr.3736openalex-snapshot
Targeted 64Cu‐labeled gold nanoparticles for dual imaging with positron emission tomography and optical imaging
inferred← citeshttps://doi.org/10.1002/jlcr.3749openalex-snapshot
Bispecific radioligands targeting prostate‐specific membrane antigen and gastrin‐releasing peptide receptors on the surface of prostate cancer cells
inferred← citeshttps://doi.org/10.1002/jlcr.3821openalex-snapshot
Manual vs automated 68Ga‐radiolabelling—A comparison of optimized processes
inferred← citeshttps://doi.org/10.1002/jlcr.3846openalex-snapshot
Automated synthesis of 68 Ga/ 177 Lu‐PSMA on the Trasis miniAllinOne
inferred← citeshttps://doi.org/10.1002/jlcr.3889openalex-snapshot
Automated radiosynthesis of [ 68 Ga]Ga‐PSMA‐11 and [ 177 Lu]Lu‐PSMA‐617 on the iPHASE MultiSyn module for clinical applications
inferred← citeshttps://doi.org/10.1002/med.21508openalex-snapshot
Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy
inferred← citeshttps://doi.org/10.1002/pros.22784openalex-snapshot
Preclinical evaluation of a bispecific low‐molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer
inferred← citeshttps://doi.org/10.1002/pros.22789openalex-snapshot
Improving the biodistribution of PSMA-targeting tracers with a highly negatively charged linker
inferred← citeshttps://doi.org/10.1002/pros.22956openalex-snapshot
Prostate‐specific membrane antigen‐based imaging in prostate cancer: Impact on clinical decision making process
inferred← citeshttps://doi.org/10.1002/pros.23091openalex-snapshot
Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68 Ga-PSMA-positron emission tomography/computerized tomography
inferred← citeshttps://doi.org/10.1002/pros.23347openalex-snapshot
68Ga‐PSMA‐PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment
inferred← citeshttps://doi.org/10.1002/pros.23642openalex-snapshot
Meeting report from the Prostate Cancer Foundation PSMA‐directed radionuclide scientific working group
inferred← citeshttps://doi.org/10.1002/pros.24056openalex-snapshot
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
inferred← citeshttps://doi.org/10.1002/pros.24294openalex-snapshot
Pilot study of the diagnostic utility of 89Zr‐df‐IAB2M and 68Ga‐PSMA‐11 PET imaging and multiparametric MRI in localized prostate cancer
inferred← citeshttps://doi.org/10.1002/slct.201902588openalex-snapshot
Evaluation of Protic Ionic Liquids Based on Triethanolammonium and Tris(hydroxymethyl)methylammonium Salts as Buffers for 68 Ga‐Radiolabelling of PSMA‐HBED‐CC
inferred← citeshttps://doi.org/10.1007/978-1-0716-3499-8_7openalex-snapshot
Rapid Radiolabeling for Peptide Radiotracers
inferred← citeshttps://doi.org/10.1007/978-3-030-39457-8_2openalex-snapshot
Radiopharmaceutical Sciences
inferred← citeshttps://doi.org/10.1007/978-3-030-39457-8_25openalex-snapshot
PSMA-Ligand Imaging in the Diagnosis of Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-030-45935-2_13openalex-snapshot
Molecular Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-05494-5_43openalex-snapshot
Diagnostic Applications of Nuclear Medicine: Prostatic Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-23205-3_12openalex-snapshot
Metal Radionuclides for Molecular Imaging
inferred← citeshttps://doi.org/10.1007/978-3-031-23205-3_14openalex-snapshot
Molecular Imaging in Oncology
inferred← citeshttps://doi.org/10.1007/978-3-031-23205-3_22openalex-snapshot
Theranostics in Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-031-33533-4_15openalex-snapshot
Precision Oncology with PSMA-Targeted α-Particle Therapy of mCRPC
inferred← citeshttps://doi.org/10.1007/978-3-031-39005-0_2openalex-snapshot
A Brief History of Radiopharmaceutical Therapy
inferred← citeshttps://doi.org/10.1007/978-3-032-21415-7_17openalex-snapshot
Clinical Applications of Theranostics
inferred← citeshttps://doi.org/10.1007/978-3-319-26067-9_43-2openalex-snapshot
Diagnostic Applications of Nuclear Medicine: Prostatic Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-26067-9_43-3openalex-snapshot
Diagnostic Applications of Nuclear Medicine: Prostatic Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-26067-9_87-1openalex-snapshot
Emerging Radiopharmaceuticals in Clinical Oncology
inferred← citeshttps://doi.org/10.1007/978-3-319-26067-9_87-2openalex-snapshot
Novel Positron Emitting Radiopharmaceuticals
inferred← citeshttps://doi.org/10.1007/978-3-319-26236-9_87openalex-snapshot
Novel Positron-Emitting Radiopharmaceuticals
inferred← citeshttps://doi.org/10.1007/978-3-319-40070-9_4openalex-snapshot
Chemistry of PET Radiopharmaceuticals: Labelling Strategies
inferred← citeshttps://doi.org/10.1007/978-3-319-42769-0_16openalex-snapshot
Postoperative Irradiation: Immediate or Early Delayed?
inferred← citeshttps://doi.org/10.1007/978-3-319-42769-0_8openalex-snapshot
Nuclear Medicine (Bone Scan, Choline and PSMA PET/CT)
inferred← citeshttps://doi.org/10.1007/978-3-319-57624-4_6openalex-snapshot
Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-64096-9_27openalex-snapshot
Molecular Imaging of Prostate Cancer: Radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT)
inferred← citeshttps://doi.org/10.1007/978-3-319-64638-1_5openalex-snapshot
Molecular Contrast Agents
inferred← citeshttps://doi.org/10.1007/978-3-319-67720-0_12openalex-snapshot
Click Chemistry for Radionanomedicine Platform
inferred← citeshttps://doi.org/10.1007/978-3-319-68517-5_19openalex-snapshot
PET/MRI in Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-93339-9_1openalex-snapshot
New Imaging Techniques in Prostate Cancer
inferred← citeshttps://doi.org/10.1007/978-3-662-50468-0_2openalex-snapshot
Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie
inferred← citeshttps://doi.org/10.1007/978-3-662-67192-4_32openalex-snapshot
Perspektiven der PET-Radiopharmaka und Bildgebung: Von FDG bis FAPi, vom PETScanner zum digitalen Ganzkörpertool
inferred← citeshttps://doi.org/10.1007/978-981-16-9535-3_7openalex-snapshot
Functional Molecular Imaging II
inferred← citeshttps://doi.org/10.1007/s00066-020-01629-5openalex-snapshot
Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
inferred← citeshttps://doi.org/10.1007/s00066-020-01660-6openalex-snapshot
Treatment outcomes of metastasis-directed treatment using 68Ga-PSMA-PET/CT for oligometastatic or oligorecurrent prostate cancer: Turkish Society for Radiation Oncology group study (TROD 09-002)
inferred← citeshttps://doi.org/10.1007/s00117-014-2792-6openalex-snapshot
68Ga-PSMA als neuer Tracer für die Evaluation des Prostatakarzinoms
inferred← citeshttps://doi.org/10.1007/s00120-016-0275-2openalex-snapshot
„PSMA-radioguided surgery“ beim lokal begrenzten Prostatakarzinomrezidiv
inferred← citeshttps://doi.org/10.1007/s00120-016-0293-0openalex-snapshot
Stellenwert der PSMA-Liganden-Bildgebung beim Prostatakarzinom
inferred← citeshttps://doi.org/10.1007/s00120-017-0516-zopenalex-snapshot
„PSMA-radioguided surgery“ beim lokalisierten Prostatakarzinomrezidiv
inferred← citeshttps://doi.org/10.1007/s00120-019-0931-4openalex-snapshot
PSA-Anstieg nach definitiver Therapie
inferred← citeshttps://doi.org/10.1007/s00259-012-2069-0openalex-snapshot
[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH
inferred← citeshttps://doi.org/10.1007/s00259-012-2298-2openalex-snapshot
PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
inferred← citeshttps://doi.org/10.1007/s00259-013-2374-2openalex-snapshot
PSMA as a target for radiolabelled small molecules
inferred← citeshttps://doi.org/10.1007/s00259-013-2385-zopenalex-snapshot
Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions
inferred← citeshttps://doi.org/10.1007/s00259-013-2489-5openalex-snapshot
PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-013-2525-5openalex-snapshot
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-013-2660-zopenalex-snapshot
Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience
inferred← citeshttps://doi.org/10.1007/s00259-014-2713-yopenalex-snapshot
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
inferred← citeshttps://doi.org/10.1007/s00259-014-2915-3openalex-snapshot
[68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice
inferred← citeshttps://doi.org/10.1007/s00259-014-2949-6openalex-snapshot
The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-015-3125-3openalex-snapshot
Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-015-3186-3openalex-snapshot
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks
inferred← citeshttps://doi.org/10.1007/s00259-015-3188-1openalex-snapshot
68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients
inferred← citeshttps://doi.org/10.1007/s00259-015-3206-3openalex-snapshot
Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-015-3240-1openalex-snapshot
Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score
inferred← citeshttps://doi.org/10.1007/s00259-015-3251-yopenalex-snapshot
Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma
inferred← citeshttps://doi.org/10.1007/s00259-015-3257-5openalex-snapshot
MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-015-3302-4openalex-snapshot
68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-016-3346-0openalex-snapshot
Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-016-3366-9openalex-snapshot
Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with 68Ga-PSMA-HBED-CC than with 18F-Fluoroethylcholine PET/CT
inferred← citeshttps://doi.org/10.1007/s00259-016-3419-0openalex-snapshot
Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing
inferred← citeshttps://doi.org/10.1007/s00259-016-3424-3openalex-snapshot
Biodistribution and radiation dosimetry of 68Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-016-3435-0openalex-snapshot
Comparison of bone scintigraphy and 68Ga-PSMA PET for skeletal staging in prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-016-3437-yopenalex-snapshot
Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand
inferred← citeshttps://doi.org/10.1007/s00259-016-3490-6openalex-snapshot
Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT
inferred← citeshttps://doi.org/10.1007/s00259-016-3572-5openalex-snapshot
Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC
inferred← citeshttps://doi.org/10.1007/s00259-016-3594-zopenalex-snapshot
Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI
inferred← citeshttps://doi.org/10.1007/s00259-017-3631-6openalex-snapshot
68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour
inferred← citeshttps://doi.org/10.1007/s00259-017-3670-zopenalex-snapshot
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
inferred← citeshttps://doi.org/10.1007/s00259-017-3746-9openalex-snapshot
Patterns of failure after radical prostatectomy in prostate cancer – implications for radiation therapy planning after 68Ga-PSMA-PET imaging
inferred← citeshttps://doi.org/10.1007/s00259-017-3780-7openalex-snapshot
Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging
inferred← citeshttps://doi.org/10.1007/s00259-017-3852-8openalex-snapshot
68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on differences between black and white South-Africans
inferred← citeshttps://doi.org/10.1007/s00259-017-3854-6openalex-snapshot
Simultaneous whole-body 18F–PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study
inferred← citeshttps://doi.org/10.1007/s00259-017-3882-2openalex-snapshot
Current status of theranostics in prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-017-3887-xopenalex-snapshot
Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy
inferred← citeshttps://doi.org/10.1007/s00259-017-3922-yopenalex-snapshot
Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives
inferred← citeshttps://doi.org/10.1007/s00259-018-3936-0openalex-snapshot
68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-018-3970-yopenalex-snapshot
Optimal time-point for 68Ga-PSMA-11 PET/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation?
inferred← citeshttps://doi.org/10.1007/s00259-019-04434-0openalex-snapshot
177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy
inferred← citeshttps://doi.org/10.1007/s00259-019-4258-6openalex-snapshot
68Ga-PSMA PET/CT for monitoring response to 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-020-04708-yopenalex-snapshot
Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy—a multicenter retrospective study
inferred← citeshttps://doi.org/10.1007/s00259-020-04718-wopenalex-snapshot
Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy
inferred← citeshttps://doi.org/10.1007/s00259-020-04760-8openalex-snapshot
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy
inferred← citeshttps://doi.org/10.1007/s00259-020-04827-6openalex-snapshot
Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients
inferred← citeshttps://doi.org/10.1007/s00259-020-05184-0openalex-snapshot
The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging
inferred← citeshttps://doi.org/10.1007/s00259-021-05245-yopenalex-snapshot
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET
inferred← citeshttps://doi.org/10.1007/s00259-021-05486-xopenalex-snapshot
68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent
inferred← citeshttps://doi.org/10.1007/s00259-021-05660-1openalex-snapshot
[68 Ga]Ga-FAPI uptake correlates with the state of chronic kidney disease
inferred← citeshttps://doi.org/10.1007/s00259-022-05743-7openalex-snapshot
A self-triggered radioligand therapy agent for fluorescence imaging of the treatment response in prostate cancer
inferred← citeshttps://doi.org/10.1007/s00259-022-05775-zopenalex-snapshot
Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging
inferred← citeshttps://doi.org/10.1007/s00259-022-05782-0openalex-snapshot
Advances in aptamer-based nuclear imaging
inferred← citeshttps://doi.org/10.1007/s00259-022-06089-wopenalex-snapshot
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
inferred← citeshttps://doi.org/10.1007/s00259-024-06726-6openalex-snapshot
Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties
inferred← citeshttps://doi.org/10.1007/s00259-024-06797-5openalex-snapshot
The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition
inferred← citeshttps://doi.org/10.1007/s00259-024-06965-7openalex-snapshot
Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA/FAP heterobivalent tracer
inferred← citeshttps://doi.org/10.1007/s00259-025-07426-5openalex-snapshot
AI lesion tracking in PET/CT imaging: a proposal for a Siamese-based CNN pipeline applied to PSMA PET/CT scans
inferred← citeshttps://doi.org/10.1007/s00259-025-07540-4openalex-snapshot
The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 68Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management
inferred← citeshttps://doi.org/10.1007/s00259-025-07623-2openalex-snapshot
[99mTc]Tc-PSMA-HSG for PSMA-targeted Hybrid Surgical Guidance: a new addition to the PSMA-I&S/I&T family
inferred← citeshttps://doi.org/10.1007/s00261-020-02745-7openalex-snapshot
Semi-automatic evaluation of baseline whole-body tumor burden as an imaging biomarker of 68Ga-PSMA-11 PET/CT in newly diagnosed prostate cancer
inferred← citeshttps://doi.org/10.1007/s00330-017-4994-6openalex-snapshot
Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT
inferred← citeshttps://doi.org/10.1007/s00330-020-07318-2openalex-snapshot
Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue
inferred← citeshttps://doi.org/10.1007/s00330-021-08140-0openalex-snapshot
Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET/MR versus PET/CT in patients with biochemically recurrent prostate cancer
inferred← citeshttps://doi.org/10.1007/s00330-023-09516-0openalex-snapshot
Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study
inferred← citeshttps://doi.org/10.1007/s00345-018-2182-1openalex-snapshot
68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review
inferred← citeshttps://doi.org/10.1007/s00345-018-2200-3openalex-snapshot
Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands
inferred← citeshttps://doi.org/10.1007/s00345-019-02701-1openalex-snapshot
68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy
inferred← citeshttps://doi.org/10.1007/s00432-021-03583-wopenalex-snapshot
Antihormone treatment differentially regulates PSA secretion, PSMA expression and 68Ga–PSMA uptake in LNCaP cells
inferred← citeshttps://doi.org/10.1007/s10354-017-0569-zopenalex-snapshot
68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?
inferred← citeshttps://doi.org/10.1007/s10585-020-10043-1openalex-snapshot
The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial
inferred← citeshttps://doi.org/10.1007/s10967-015-4623-2openalex-snapshot
Radio-synthesis and mass spectrometry analysis of 68Ga-DKFZ-PSMA-617 for non-invasive prostate cancer PET imaging
inferred← citeshttps://doi.org/10.1007/s10967-022-08301-5openalex-snapshot
Preclinical development of a novel [68Ga]Ga-/[177Lu]Lu-labeled agent for PSMA-targeted imaging and therapy
inferred← citeshttps://doi.org/10.1007/s10967-022-08624-3openalex-snapshot
Radiometal-theranostics: the first 20 years*
inferred← citeshttps://doi.org/10.1007/s11094-015-1184-1openalex-snapshot
Metal Complexes with Ethylenediaminedicarboxylic Acids and Their Derivatives, Promising Pharmacological and Diagnostic Agents (Review)
inferred← citeshttps://doi.org/10.1007/s11255-025-04780-zopenalex-snapshot
Can 68Ga-PSMA-11 PET/CT renal uptake parameters predict renal function impairment?
inferred← citeshttps://doi.org/10.1007/s11307-015-0850-8openalex-snapshot
Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s11307-015-0866-0openalex-snapshot
Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s11307-016-0942-0openalex-snapshot
Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617
inferred← citeshttps://doi.org/10.1007/s11307-017-1091-9openalex-snapshot
Repeatability of [68Ga]DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s11307-017-1101-yopenalex-snapshot
[68Ga]PSMA-HBED-CC Uptake in Osteolytic, Osteoblastic, and Bone Marrow Metastases of Prostate Cancer Patients
inferred← citeshttps://doi.org/10.1007/s11307-018-1263-2openalex-snapshot
Combined Early and Late [68Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels
inferred← citeshttps://doi.org/10.1007/s11307-018-1278-8openalex-snapshot
[68Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s11547-018-0929-9openalex-snapshot
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer
inferred← citeshttps://doi.org/10.1007/s11548-016-1385-4openalex-snapshot
Robust augmented reality guidance with fluorescent markers in laparoscopic surgery
inferred← citeshttps://doi.org/10.1007/s11604-024-01646-9openalex-snapshot
PSMA PET/CT imaging and its application to prostate cancer treatment
inferred← citeshttps://doi.org/10.1007/s11864-024-01181-9openalex-snapshot
Impact of PSMA PET on Prostate Cancer Management
inferred← citeshttps://doi.org/10.1007/s11912-021-01042-wopenalex-snapshot
Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s11912-025-01686-yopenalex-snapshot
Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions
inferred← citeshttps://doi.org/10.1007/s11934-013-0389-7openalex-snapshot
Lymphotropic Nanoparticle-enhanced MRI in Prostate Cancer: Value and Therapeutic Potential
inferred← citeshttps://doi.org/10.1007/s11934-019-0938-9openalex-snapshot
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
inferred← citeshttps://doi.org/10.1007/s12149-019-01360-xopenalex-snapshot
The role of (68Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUVmax
inferred← citeshttps://doi.org/10.1007/s12149-024-01931-7openalex-snapshot
Evaluation of 68Ga-PSMA-11 PET/CT: a Phase 1 clinical study in Japanese patients with primary, recurrent, or suspected recurrent prostate cancer
inferred← citeshttps://doi.org/10.1007/s12149-026-02193-1openalex-snapshot
Lesion-level quantitative Lu-177 PSMA SPECT/CT SUV metrics are associated with interim treatment response in mCRPC: a PET-correlated study
inferred← citeshttps://doi.org/10.1007/s12149-026-02195-zopenalex-snapshot
Non-metastatic castration-resistant prostate cancer in the epoch of PSMA-ligand PET/CT: twilight?
inferred← citeshttps://doi.org/10.1007/s12312-016-0040-xopenalex-snapshot
Diagnose und Ausbreitungsdiagnostik des Prostatakarzinoms
inferred← citeshttps://doi.org/10.1007/s12551-021-00919-1openalex-snapshot
Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors
inferred← citeshttps://doi.org/10.1007/s13139-025-00963-9openalex-snapshot
Current Status and Advancements in Radiotheranostics and Targeted Radionuclide Therapy in Malaysia
inferred← citeshttps://doi.org/10.1007/s13246-024-01402-3openalex-snapshot
Machine learning-based analysis of 68Ga-PSMA-11 PET/CT images for estimation of prostate tumor grade
inferred← citeshttps://doi.org/10.1007/s40261-022-01178-yopenalex-snapshot
Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
inferred← citeshttps://doi.org/10.1007/s40336-014-0048-0openalex-snapshot
Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics
inferred← citeshttps://doi.org/10.1007/s40336-016-0194-7openalex-snapshot
PET imaging in prostate cancer, future trends: PSMA ligands
inferred← citeshttps://doi.org/10.1007/s40336-019-00326-3openalex-snapshot
Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: an overview
inferred← citeshttps://doi.org/10.1007/s40336-021-00478-1openalex-snapshot
PSMA PET/CT and radiotherapy in prostate cancer: a winning team
inferred← citeshttps://doi.org/10.1007/s40336-024-00631-6openalex-snapshot
Equivocal bone lesions on PSMA PET/CT: systematic review and meta-analysis on their prevalence and malignancy rate
inferred← citeshttps://doi.org/10.1007/s40336-025-00712-0openalex-snapshot
Intra-individual comparison of PSMA PET and whole-body MRI in patients with biochemically recurrent prostate cancer
inferred← citeshttps://doi.org/10.1007/s40615-026-02993-1openalex-snapshot
68Ga-PSMA-11 PET/CT for Detecting Biochemical Recurrence after Radical Prostatectomy in a Racially Diverse Population with Low PSA Levels
inferred← citeshttps://doi.org/10.1007/s41365-016-0134-2openalex-snapshot
Preparation and biodistribution assessment of 68Ga-DKFZ-PSMA-617 for PET prostate cancer imaging
inferred← citeshttps://doi.org/10.1007/s44211-024-00514-wopenalex-snapshot
Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics
inferred← citeshttps://doi.org/10.1016/b978-0-12-407722-5.00017-7openalex-snapshot
Radionuclides for Imaging and Therapy in Oncology
inferred← citeshttps://doi.org/10.1016/b978-0-12-822960-6.00111-3openalex-snapshot
PET imaging of prostate cancer
inferred← citeshttps://doi.org/10.1016/b978-0-323-98377-8.00002-6openalex-snapshot
Therapeutic management of hormone-dependent cancers in transgender patients
inferred← citeshttps://doi.org/10.1016/b978-0-443-22253-5.00019-4openalex-snapshot
Image-guided surgery of cancer
inferred← citeshttps://doi.org/10.1016/b978-0-443-22253-5.00026-1openalex-snapshot
Radionuclides for imaging and therapy in oncology
inferred← citeshttps://doi.org/10.1016/b978-2-294-78189-6.00011-6openalex-snapshot
Indications actuelles de l’imagerie hybride TEP-IRM corps entier
inferred← citeshttps://doi.org/10.1016/bs.adioch.2019.11.001openalex-snapshot
150 years of the periodic table: New medicines and diagnostic agents
inferred← citeshttps://doi.org/10.1016/bs.adioch.2021.05.002openalex-snapshot
Metallic radionuclides for diagnostic imaging and cancer radiotherapy: The development of theragnostic matched pairs and targeted alpha therapy
inferred← citeshttps://doi.org/10.1016/j.aca.2017.10.008openalex-snapshot
Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy
showing the first 200 of 829 · page through all 829
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.